Friday, 16 Feb 2018

You are here

Obesity Outweighs Psoriasis in Comorbidity Risk with Children

Like their adult counterparts, psoriasis in children is an independent risk factor for comorbidity, but not as much as  obesity.

Using claims data from Optum Laboratories Data Warehouse (150 million privately insured and Medicare enrollees), of 29 957 children with psoriasis were matched with a comparator cohort (children without psoriasis) and studied for the effects of psoriasis and obsesity. 

Psoriasis children were likely to be obese (2.9% vs 1.5%; P < .001). They were also significantly more likely to develop each of the studied comorbidities than those without psoriasis (P < .01).

In nonobese children, psoriasis was associated with a 40% to 75% risk of comorbidity:

  • Hyperlipidemia - HR, 1.42; 95% CI, 1.25-1.62
  • HTN - HR, 1.64; 95% CI, 1.40-1.93
  • Diabetes - HR, 1.58; 95% CI, 1.27-1.95
  • Metabolic syndrome -  HR, 1.62; 95% CI, 1.13-2.33
  • Polycystic ovarian syndrome - HR, 1.49; 95% CI, 1.18-1.88
  • Nonalcoholic liver disease (HR, 1.76; 95% CI, 1.16-2.65
  • Elevated liver enzymes - HR, 1.46; 95% CI, 1.27-1.67

 

Obesity was a strong risk factor for development of comorbidity, even without psoriasis (HR ranging from 2.26 to 18.11).

Children with psoriasis are at greater risk of developing obesity, hyperlipidemia, hypertension, diabetes, metabolic syndrome, polycystic ovarian syndrome, nonalcoholic liver disease, and elevated liver function enzyme levels than children without psoriasis.

However, obesity is a much stronger risk factor for comorbidity in children with psoriasis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures

An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients. 

PRESERVE Study: HAQ, BMI and Age Predict Responses to Combo Therapy

Rheumatoid arthritis patients who were younger and who had lower body mass index, Health Assessment Questionnaire (HAQ) scores, and less disease activity at baseline were most likely to achieve remission after combination etanercept (Enbrel) and methotrexate induction therapy, a post hoc analysis of the PRESERVE trial found.

Why TNF Inhibitors May Work in Some Autoinflammatory Patients

The NLRP3 inflammasome is a critical component of the innate immune system and activation of NLRP3 inflammasome results in caspase-1–dependent secretion of the proinflammatory cytokines IL-1β and IL-18. Gain-of-function missense mutations in NLRP3 is thought to drive many of the autoinflammatory diseases, especially the cryopyrin-associated periodic syndromes (CAPS).

Infliximab Does Not Increase Perioperative Infection

Staying on a TNF inhibitor (TNFi) throughout major surgery has generatlly been associated with higher rates of perioperative infection (https://buff.ly/2iBFVjp).  On the other hand, discontinuation of the TNFi prior to surgery is associated with lower rates of  infection (https://buff.ly/2iAFZQf)

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein. But Lancet has now reported a clinical trial has shown that a tight control strategy can yield better responses to TNF inhibitors when compared to usual care.